Mar. 13 at 2:13 PM
$AXSM Reviewing the weekly TRx data for Auvelity shows strong and consistent year over year growth. In early 2024 the drug generated ~5,600–6,700 scripts per week, which nearly doubled by the same weeks in 2025 to ~10,000–12,800. The 2026 data shows another clear step higher, with weekly scripts generally in the ~15,000–17,000 range. Through the first ten weeks of the quarter, 2026 scripts are running ~30% ahead of the same period in 2025, indicating continued adoption.
Another important item is the emergence of a higher baseline. During 2025 weekly TRx clustered around ~12,000–13,000, while 2026 has shifted that range upward to ~15,000–17,000. This pattern is typical of a drug moving from early adoption to broader commercial expansion as the refill base grows. The data also shows seasonality, with Q4 historically producing the strongest weekly script levels.
